Codexis Inc (CDXS) 4.78 $CDXS
Grainger (GWW) to Grow on Sales Initiatives, Risks Linger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:27PM CDT
On Apr 21, 2015, we issued an updated research report on W.W. Grainger Inc. (GWW).
CDXS: 4.78 (+0.30), GWW: 243.45 (+0.44), ROLL: 75.54 (+0.32), AOS: 65.83 (+0.41)
Will Caterpillar (CAT) Beat Earnings Estimates in Q1? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 1:56PM CDT
Caterpillar Inc. (CAT) will release its first-quarter 2015 financial results before the opening bell on Apr 23.
BWC: 32.55 (+0.17), CDXS: 4.78 (+0.30), IR: 67.49 (+0.29), CAT: 84.87 (+0.95)
BUYINS.NET: CDXS SqueezeTrigger Price is $5.02. There is $2,424,884 That Short Sellers Still Need To Cover.
M2 - Mon Apr 20, 6:26AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Codexis Inc (NASDAQ:CDXS) in real time and just received an alert that CDXS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 479700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $5.02. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
CDXS: 4.78 (+0.30)
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HBNK: 22.21 (-0.41), EVOK: 6.43 (-0.08), ADXS: 22.18 (+0.10), PTX: 7.44 (-0.05), ANGI: 6.46 (+0.31), CDXS: 4.78 (+0.30), AKBA: 8.39 (+0.07), PCRX: 83.61 (-0.41), OTIC: 32.83 (unch)
Precision Unveils Q4 Asset Charges & Restructuring Actions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:20PM CDT
Precision Castparts Corp. (PCP), recently reviewed its oil & gas, and power pipe end-markets and inventories to reveal certain asset-rationalization charges as well as restructuring operations for fiscal fourth-quarter 2015.
CDXS: 4.78 (+0.30), PCP: 204.84 (+0.10)
Grainger's Q1 Earnings, Revenues Trail Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 9:53AM CDT
W.W. Grainger, Inc. (GWW) reported first quarter earnings and sales both fell short of the Zacks Consensus Estimates.
CDXS: 4.78 (+0.30), GWW: 243.45 (+0.44), ROLL: 75.54 (+0.32), ASTE: 42.80 (+0.16)
Will Codexis (CDXS) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 8:03AM CDT
Will Codexis (CDXS) Continue to Surge Higher?
CDXS: 4.78 (+0.30)
BUYINS.NET: CDXS SqueezeTrigger Price is $5.02. There is $2,412,891 That Short Sellers Still Need To Cover.
M2 - Tue Apr 14, 3:03AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Codexis Inc (NASDAQ:CDXS) in real time and just received an alert that CDXS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 479700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $5.02. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
CDXS: 4.78 (+0.30)
Global Biocatalysis & Biocatalysts Market Report 2015-2019 with Novozymes, DuPont & DSM Featuring as the Most Active Players
M2 - Wed Mar 11, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxtvw4/biocatalysis_and) has announced the addition of the "Biocatalysis & Biocatalysts Market By Type (Hydrolases, Oxidoreductases, Transferases, And Others), Application (Food & Beverages, Cleaning Agents, Agriculture & Feed, Biofuel Production, Biopharmaceuticals, And Others), and Geography - Forecast to 2019 " report to their offering. The biocatalysts market was estimated around 81 kilo tons in 2013, with the high share of around 70% held by North America and Europe together. The global biocatalysts market by volume is projected to grow at a CAGR of 5.5% from 2014 to 2019. The high growth is forecasted to be in the RoW due to rise of end industries such as biofuel production, agriculture & feed, food and beverages in the region. Europe is estimated to have the second highest growth around 6.71% from 2014 to 2019. Advancements in the biocatalysis process have led to increased penetration of biocatalysts in different applications. Biofuel and detergent industries have the largest application of biocatalysts. Food & beverages, agriculture & feed, biopharmaceuticals are the other significant applications. Small applications include life science applications, textile, leather, pulp & paper, and flavor & fragrances. Biofuel and biopharmaceuticals applications are predicted to show the highest growth rate in the next five years. Hydrolases, transferases, and oxidoreductases are the major types of biocatalysts. The other three segments of biocatalysts lyases, isomerases, and ligases are small part of the biocatalysts market currently. The biocatalysts market is anticipated to show a high growth rate in the coming years. The market is innovation driven and investments are expected for new biocatalysis process and enzyme development. There are large numbers of various sized players in the market but it is dominated by few big companies. Currently, the biocatalyst market is mainly concentrated in the North American and European region while RoW region, especially Latin America is expected to show high growth rate in future years. Advancement in biocatalysis process along with increasing penetration of biocatalysts in different applications is driving the growth of the global biocatalysts market. Novozymes (Denmark), DuPont (U.S.), DSM (Netherlands) are the important active players in the biocatalysts market. These companies showed the highest strategy adoptions amongst other players in the biocatalysts market from 2010 to 2014. These companies together hold around 70% share of the biocatalysts market. From 2010 to 2014, partnership, agreement, and collaboration was observed as the most important growth strategy adopted by the major biocatalysts, accounting for a share of more than 50% of the total strategies adopted by the players. The other companies AB Enzymes (Germany), Codexis Inc. (U.S.), and BASF (Germany) also contributed to the market activities in the global biocatalysts market during the above mentioned period. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Biocatalysis And Biocatalysts Market, By Type 8 Biocatalysis And Biocatalysts Market, By Application 9 Regional Analysis 10 Competitive Landscape 11 Company Profiles - Ab Enzymes Gmbh - Amano Enzymes - Basf Se - Chr. Hansen - Codexis Inc. - Dyadic International - E.I. Dupont De Nemours & Co. - Novozymes A/S - Royal Dsm N.V. - Soufflet Group For more information visit http://www.researchandmarkets.com/research/fx...alysis_and
CDXS: 4.78 (+0.30)
Codexis (CDXS) in Focus: Stock Falls 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 7:31AM CDT
Codexis saw a big move last session, as the company’s shares fell by over 7% on the day.
CDXS: 4.78 (+0.30), ABGB: 16.42 (-0.25)
Codexis' (CDXS) CEO John Nicols on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 7:16PM CST
CDXS: 4.78 (+0.30)
Codexis posts 4Q profit
Automated Insights - Tue Mar 03, 4:13PM CST
REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Tuesday reported fourth-quarter net income of $345,000, after reporting a loss in the same period a year earlier.
CDXS: 4.78 (+0.30)
Codexis (CDXS) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:25PM CST
CDXS: 4.78 (+0.30)
Codexis beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:14PM CST
CDXS: 4.78 (+0.30)
Codexis to Present at ROTH Conference
GlobeNewswire - Tue Mar 03, 7:00AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 27 Annual ROTH Conference on Tuesday, March 10, 2015, at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time). The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
CDXS: 4.78 (+0.30)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:35PM CST
AMBA: 74.57 (+0.18), BV: 5.87 (+0.07), AMRN: 2.34 (-0.05), AVAV: 26.36 (+0.14), BOBE: 44.21 (+0.49), TNET: 35.45 (-0.54), CECO: 4.80 (-0.09), VEEV: 27.12 (+0.28), REGI: 8.94 (+0.08), TIVO: 11.08 (+0.03), EGL: 30.03 (-0.32), ZLTQ: 33.42 (-0.59), LRE: 8.43 (+0.08), GERN: 4.20 (-0.04), ASNA: 15.03 (-0.07), CDXS: 4.78 (+0.30), SWHC: 14.68 (-0.12), ABM: 31.87 (-0.15)
Phenylketonuria (PKU) Therapeutics Pipeline Review 2015 - Analysis of 5 Companies & 6 Drug Profiles
M2 - Mon Mar 02, 6:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/rz4mm7/phenylketonuria) has announced the addition of the "Phenylketonuria (PKU) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Phenylketonuria (PKU), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Phenylketonuria (PKU) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Phenylketonuria (PKU) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Phenylketonuria (PKU) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Phenylketonuria (PKU) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - BioMarin Pharmaceutical Inc. - Codexis, Inc. - Erytech Pharma SA - Promethera Biosciences S.A. - SOM Innovation Biotech SL Drug Profiles - BMN-165 - Cell therapy for Phenylketonuria - HepaStem - Recombinant Enzyme to Replace Phenylalanine Hydroxylase for Phenyketonuria - sapropterin dihydrochloride - SOM-7400 For more information visit http://www.researchandmarkets.com/research/rz...lketonuria
BMRN: 121.08 (-0.16), CDXS: 4.78 (+0.30)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 35.08 (+0.25), CASM: 1.30 (unch), AMRN: 2.34 (-0.05), XON: 44.53 (+0.36), OSIR: 16.35 (-0.10), CPIX: 6.95 (+0.02), AMED: 26.07 (+0.03), CTIC: 1.93 (+0.09), INSY: 62.10 (+0.76), ECYT: 6.37 (unch), CMRX: 39.73 (+0.65), KYTH: 49.94 (+0.78), TRIB: 17.17 (-0.17), GALE: 1.39 (unch), ARNA: 4.47 (+0.01), XLRN: 33.67 (-0.02), ACRX: 4.50 (-0.07), ENDP: 94.09 (-1.09), DPLO: 34.52 (+0.26), SLXP: 172.96 (+0.15), PPHM: 1.42 (-0.01), MYL: 72.40 (-1.67), CBPO: 99.67 (-0.84), RGEN: 33.37 (+0.51), HALO: 16.03 (+0.15), ALIM: 4.92 (-0.09), ACHN: 10.01 (-0.13), GERN: 4.20 (-0.04), DARA: 0.75 (+0.02), SCMP: 21.75 (+0.47), ICPT: 280.45 (-8.26), CDXS: 4.78 (+0.30), PCRX: 83.61 (-0.41), PBYI: 225.63 (-4.24), FOLD: 11.97 (-0.35)
Numerous Catalysts For Codexis
Brandon Vara - Seeking Alpha - Tue Feb 17, 8:24AM CST
Codexis, Inc. (NASDAQ: CDXS ) is a microcap biotechnology company ($140M) with roughly 125 employees - a number that has been growing pretty steadily since its launch in 2002. The company has arguably been under the radar the past couple of years due...
MRK: 57.69 (+0.03), CDXS: 4.78 (+0.30), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67)
Codexis to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:27PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). The conference is being held at the Waldorf Astoria in New York City.
CDXS: 4.78 (+0.30)
Grainger (GWW) to Grow on Sales Initiatives, Risks Linger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:27PM CDT
On Apr 21, 2015, we issued an updated research report on W.W. Grainger Inc. (GWW).
CDXS: 4.78 (+0.30), GWW: 243.45 (+0.44), ROLL: 75.54 (+0.32), AOS: 65.83 (+0.41)
Will Caterpillar (CAT) Beat Earnings Estimates in Q1? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 1:56PM CDT
Caterpillar Inc. (CAT) will release its first-quarter 2015 financial results before the opening bell on Apr 23.
BWC: 32.55 (+0.17), CDXS: 4.78 (+0.30), IR: 67.49 (+0.29), CAT: 84.87 (+0.95)
BUYINS.NET: CDXS SqueezeTrigger Price is $5.02. There is $2,424,884 That Short Sellers Still Need To Cover.
M2 - Mon Apr 20, 6:26AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Codexis Inc (NASDAQ:CDXS) in real time and just received an alert that CDXS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 479700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $5.02. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
CDXS: 4.78 (+0.30)
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HBNK: 22.21 (-0.41), EVOK: 6.43 (-0.08), ADXS: 22.18 (+0.10), PTX: 7.44 (-0.05), ANGI: 6.46 (+0.31), CDXS: 4.78 (+0.30), AKBA: 8.39 (+0.07), PCRX: 83.61 (-0.41), OTIC: 32.83 (unch)
Precision Unveils Q4 Asset Charges & Restructuring Actions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:20PM CDT
Precision Castparts Corp. (PCP), recently reviewed its oil & gas, and power pipe end-markets and inventories to reveal certain asset-rationalization charges as well as restructuring operations for fiscal fourth-quarter 2015.
CDXS: 4.78 (+0.30), PCP: 204.84 (+0.10)
Grainger's Q1 Earnings, Revenues Trail Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 9:53AM CDT
W.W. Grainger, Inc. (GWW) reported first quarter earnings and sales both fell short of the Zacks Consensus Estimates.
CDXS: 4.78 (+0.30), GWW: 243.45 (+0.44), ROLL: 75.54 (+0.32), ASTE: 42.80 (+0.16)
Will Codexis (CDXS) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 8:03AM CDT
Will Codexis (CDXS) Continue to Surge Higher?
CDXS: 4.78 (+0.30)
BUYINS.NET: CDXS SqueezeTrigger Price is $5.02. There is $2,412,891 That Short Sellers Still Need To Cover.
M2 - Tue Apr 14, 3:03AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Codexis Inc (NASDAQ:CDXS) in real time and just received an alert that CDXS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 479700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $5.02. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
CDXS: 4.78 (+0.30)
Global Biocatalysis & Biocatalysts Market Report 2015-2019 with Novozymes, DuPont & DSM Featuring as the Most Active Players
M2 - Wed Mar 11, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxtvw4/biocatalysis_and) has announced the addition of the "Biocatalysis & Biocatalysts Market By Type (Hydrolases, Oxidoreductases, Transferases, And Others), Application (Food & Beverages, Cleaning Agents, Agriculture & Feed, Biofuel Production, Biopharmaceuticals, And Others), and Geography - Forecast to 2019 " report to their offering. The biocatalysts market was estimated around 81 kilo tons in 2013, with the high share of around 70% held by North America and Europe together. The global biocatalysts market by volume is projected to grow at a CAGR of 5.5% from 2014 to 2019. The high growth is forecasted to be in the RoW due to rise of end industries such as biofuel production, agriculture & feed, food and beverages in the region. Europe is estimated to have the second highest growth around 6.71% from 2014 to 2019. Advancements in the biocatalysis process have led to increased penetration of biocatalysts in different applications. Biofuel and detergent industries have the largest application of biocatalysts. Food & beverages, agriculture & feed, biopharmaceuticals are the other significant applications. Small applications include life science applications, textile, leather, pulp & paper, and flavor & fragrances. Biofuel and biopharmaceuticals applications are predicted to show the highest growth rate in the next five years. Hydrolases, transferases, and oxidoreductases are the major types of biocatalysts. The other three segments of biocatalysts lyases, isomerases, and ligases are small part of the biocatalysts market currently. The biocatalysts market is anticipated to show a high growth rate in the coming years. The market is innovation driven and investments are expected for new biocatalysis process and enzyme development. There are large numbers of various sized players in the market but it is dominated by few big companies. Currently, the biocatalyst market is mainly concentrated in the North American and European region while RoW region, especially Latin America is expected to show high growth rate in future years. Advancement in biocatalysis process along with increasing penetration of biocatalysts in different applications is driving the growth of the global biocatalysts market. Novozymes (Denmark), DuPont (U.S.), DSM (Netherlands) are the important active players in the biocatalysts market. These companies showed the highest strategy adoptions amongst other players in the biocatalysts market from 2010 to 2014. These companies together hold around 70% share of the biocatalysts market. From 2010 to 2014, partnership, agreement, and collaboration was observed as the most important growth strategy adopted by the major biocatalysts, accounting for a share of more than 50% of the total strategies adopted by the players. The other companies AB Enzymes (Germany), Codexis Inc. (U.S.), and BASF (Germany) also contributed to the market activities in the global biocatalysts market during the above mentioned period. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Biocatalysis And Biocatalysts Market, By Type 8 Biocatalysis And Biocatalysts Market, By Application 9 Regional Analysis 10 Competitive Landscape 11 Company Profiles - Ab Enzymes Gmbh - Amano Enzymes - Basf Se - Chr. Hansen - Codexis Inc. - Dyadic International - E.I. Dupont De Nemours & Co. - Novozymes A/S - Royal Dsm N.V. - Soufflet Group For more information visit http://www.researchandmarkets.com/research/fx...alysis_and
CDXS: 4.78 (+0.30)
Codexis (CDXS) in Focus: Stock Falls 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 7:31AM CDT
Codexis saw a big move last session, as the company’s shares fell by over 7% on the day.
CDXS: 4.78 (+0.30), ABGB: 16.42 (-0.25)
Codexis' (CDXS) CEO John Nicols on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 7:16PM CST
CDXS: 4.78 (+0.30)
Codexis posts 4Q profit
Automated Insights - Tue Mar 03, 4:13PM CST
REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Tuesday reported fourth-quarter net income of $345,000, after reporting a loss in the same period a year earlier.
CDXS: 4.78 (+0.30)
Codexis (CDXS) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:25PM CST
CDXS: 4.78 (+0.30)
Codexis beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:14PM CST
CDXS: 4.78 (+0.30)
Codexis to Present at ROTH Conference
GlobeNewswire - Tue Mar 03, 7:00AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 27 Annual ROTH Conference on Tuesday, March 10, 2015, at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time). The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
CDXS: 4.78 (+0.30)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:35PM CST
AMBA: 74.57 (+0.18), BV: 5.87 (+0.07), AMRN: 2.34 (-0.05), AVAV: 26.36 (+0.14), BOBE: 44.21 (+0.49), TNET: 35.45 (-0.54), CECO: 4.80 (-0.09), VEEV: 27.12 (+0.28), REGI: 8.94 (+0.08), TIVO: 11.08 (+0.03), EGL: 30.03 (-0.32), ZLTQ: 33.42 (-0.59), LRE: 8.43 (+0.08), GERN: 4.20 (-0.04), ASNA: 15.03 (-0.07), CDXS: 4.78 (+0.30), SWHC: 14.68 (-0.12), ABM: 31.87 (-0.15)
Phenylketonuria (PKU) Therapeutics Pipeline Review 2015 - Analysis of 5 Companies & 6 Drug Profiles
M2 - Mon Mar 02, 6:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/rz4mm7/phenylketonuria) has announced the addition of the "Phenylketonuria (PKU) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Phenylketonuria (PKU), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Phenylketonuria (PKU) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Phenylketonuria (PKU) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Phenylketonuria (PKU) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Phenylketonuria (PKU) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - BioMarin Pharmaceutical Inc. - Codexis, Inc. - Erytech Pharma SA - Promethera Biosciences S.A. - SOM Innovation Biotech SL Drug Profiles - BMN-165 - Cell therapy for Phenylketonuria - HepaStem - Recombinant Enzyme to Replace Phenylalanine Hydroxylase for Phenyketonuria - sapropterin dihydrochloride - SOM-7400 For more information visit http://www.researchandmarkets.com/research/rz...lketonuria
BMRN: 121.08 (-0.16), CDXS: 4.78 (+0.30)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 35.08 (+0.25), CASM: 1.30 (unch), AMRN: 2.34 (-0.05), XON: 44.53 (+0.36), OSIR: 16.35 (-0.10), CPIX: 6.95 (+0.02), AMED: 26.07 (+0.03), CTIC: 1.93 (+0.09), INSY: 62.10 (+0.76), ECYT: 6.37 (unch), CMRX: 39.73 (+0.65), KYTH: 49.94 (+0.78), TRIB: 17.17 (-0.17), GALE: 1.39 (unch), ARNA: 4.47 (+0.01), XLRN: 33.67 (-0.02), ACRX: 4.50 (-0.07), ENDP: 94.09 (-1.09), DPLO: 34.52 (+0.26), SLXP: 172.96 (+0.15), PPHM: 1.42 (-0.01), MYL: 72.40 (-1.67), CBPO: 99.67 (-0.84), RGEN: 33.37 (+0.51), HALO: 16.03 (+0.15), ALIM: 4.92 (-0.09), ACHN: 10.01 (-0.13), GERN: 4.20 (-0.04), DARA: 0.75 (+0.02), SCMP: 21.75 (+0.47), ICPT: 280.45 (-8.26), CDXS: 4.78 (+0.30), PCRX: 83.61 (-0.41), PBYI: 225.63 (-4.24), FOLD: 11.97 (-0.35)
Numerous Catalysts For Codexis
Brandon Vara - Seeking Alpha - Tue Feb 17, 8:24AM CST
Codexis, Inc. (NASDAQ: CDXS ) is a microcap biotechnology company ($140M) with roughly 125 employees - a number that has been growing pretty steadily since its launch in 2002. The company has arguably been under the radar the past couple of years due...
MRK: 57.69 (+0.03), CDXS: 4.78 (+0.30), AMGN: 169.10 (+0.64), GSK: 46.57 (-0.67)
Codexis to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:27PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). The conference is being held at the Waldorf Astoria in New York City.
CDXS: 4.78 (+0.30)
